Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical Data has obtained US patent no.7,834,020 claiming the polymorphic form of Vilazodone (Vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.
Subscribe to our email newsletter
Clinical Data said that the issued patent, which will expire in June 2022, covers Vilazodone HC1 in Form IV, its process of preparation and method of treatment therewith.
The company said that the issued patent extends exclusive protection in the US of the most commercially viable polymorphic form of Vilazodone nearly three additional years beyond the projected allowable patent term extension of the composition of matter patent for the chemical structure of Vilazodone.
Clinical Data president and CEO Drew Fromkin said that this patent is an important addition to the intellectual property estate for Vilazodone, providing even greater protection for the product as they continue to advance the preparations for a commercial launch, upon approval, next year.
"Adding three additional years of exclusivity for the key polymorphic form of a drug that has blockbuster potential and for which the company holds exclusive worldwide rights should have a very positive impact on the value of Clinical Data going forward, Fromkin said.
"Our strategies for securing further market exclusivity for Vilazodone are also progressing, and we anticipate that related, additional claims are likely to be issued in the future."